MedGenome, the Leading South Asian Genetic Diagnostics, Research and Data Company Announces USD 55m Investment Led by LeapFrog

- MedGenome is the largest provider of genomic solutions for populations in South Asia and Emerging Markets- The investment will expand access and affordability of genetic testing services across India- Globally, the investment will drive creation of more diverse datasets and enable discovery of novel drug targetsFOSTER CITY, California, April 1, 2020 /PRNewswire/ -- MedGenome, the leading genetic diagnostics, research and data company focused on expanding access for populations in South Asia and other emerging markets today announced an investment of USD 55m led by LeapFrog Investments, a leading specialist investor in emerging markets. Existing investors Sofina and Sequoia also participated in the round.Sam Santhosh, the CEO and Founder of MedGenome, said, "Genomics and personalized medicine are the future of healthcare, but emerging markets remain significantly under-penetrated. As the largest player in India in applied genomics, we are well-positioned to fill this gap." The subcontinent contributes around 20% of the world's population, while the DNA sequences of its people make up only around 0.2% of global genetic databases.
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Июнь 2020    »